This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

QIAGEN's CEO Hosts Investor Day - Conference Call Transcript

So if you walk the floors of, for instance, AMP, people will be talking about processing anything from blood samples, to plasma samples, to tissue samples of different forms, fresh tissue, FFPE tissues. They’ll be talking about stool and urine samples. They’ll be talking about anything under the sun basically that contains genetic information that has to be processed.

Now this is not a simple process, but needs a very diverse technology portfolio. And our expertise always has been and is now increasingly showing value, the ability to create a funnel to take raw biology into an analyte that can be ultimately then analyzed using our assay technology. So this transition from a component supplier to a work flow supplier covering all of these different workflow elements was key and that happened over the last 10 years.

If we look at where the various players are active, that has been changing as well. So the academic sector has been reaching out beyond by basic research and biomarkers into translational medicine even into clinical trials. If you read about some of the initiatives that are happening here in the United States but also many other countries of the world, the academic sector is reaching into clinical development expanding beyond clinical research into routine clinical development even, and in some cases even pursuing drug development. This is a new trend.

At the same time, molecular diagnostics and this is also evident here from AMP is going much deeper into the earlier phases of research. So moving through the translational medicine field even into biomarker and in some cases even looking at basic biological research. But this trend is one that the pharmaceutical industry is now looking at in more detail because their challenges here in the middle, in the translational medicine and clinical trial and approval area to basically translate that basic research into routine products and they are also relying on the various pillars that are used across this continuum. The only area that is more traditional like the diagnostics industry was let say, 10 years or 15 years ago, very strong compartmentalization is the applied testing field which is less linked to the research or even the development world.

6 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs